OpenAI acquires Orchestra Bio
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, aiming to help biopharma teams speed up drug development. The deal amount was not disclosed.
Every Orchestra Bio story collected by The AI Daily, 1 so far, newest first, refreshed hourly.
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, aiming to help biopharma teams speed up drug development. The deal amount was not disclosed.